CD274 and non-small cell lung carcinoma: In addition to 18F-fluorodeoxyglucose (30), 18F-labeled anti-PD-L1 adnectin, 89Zr-labeled nivolumab (31), and 99mTc-labeled anti-PD-L1 single-domain antibody (32), our study also provides clinical physicians with a new non-invasive measurements of PD-L1, which may be useful in guiding ICI treatment in NSCLC.